GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » ROA %

HighTide Therapeutics (HKSE:02511) ROA % : -100.30% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. HighTide Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-852.19 Mil. HighTide Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was HK$849.66 Mil. Therefore, HighTide Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -100.30%.

The historical rank and industry rank for HighTide Therapeutics's ROA % or its related term are showing as below:

HKSE:02511' s ROA % Range Over the Past 10 Years
Min: -116.09   Med: -28.4   Max: -22.26
Current: -116.09

During the past 3 years, HighTide Therapeutics's highest ROA % was -22.26%. The lowest was -116.09%. And the median was -28.40%.

HKSE:02511's ROA % is ranked worse than
86.6% of 1552 companies
in the Biotechnology industry
Industry Median: -34.65 vs HKSE:02511: -116.09

HighTide Therapeutics ROA % Historical Data

The historical data trend for HighTide Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics ROA % Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROA %
-28.40 -22.26 -112.57

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROA % - -18.24 -27.12 -134.71 -100.30

Competitive Comparison of HighTide Therapeutics's ROA %

For the Biotechnology subindustry, HighTide Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's ROA % falls into.



HighTide Therapeutics ROA % Calculation

HighTide Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-1027.393/( (955.711+869.594)/ 2 )
=-1027.393/912.6525
=-112.57 %

HighTide Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-852.19/( (829.722+869.594)/ 2 )
=-852.19/849.658
=-100.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


HighTide Therapeutics  (HKSE:02511) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-852.19/849.658
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-852.19 / 0)*(0 / 849.658)
=Net Margin %*Asset Turnover
=N/A %*0
=-100.30 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


HighTide Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines